Melanoma – Pipeline Review, H2 2016
- Pages: 1656
- Published: December 2016
- Report Code: GMDHC8868IDB
Global Markets Direct’s, ‘Melanoma – Pipeline Review, H2 2016’, provides an overview of the Melanoma pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Melanoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Melanoma and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
The report provides a snapshot of the global therapeutic landscape of Melanoma
The report reviews pipeline therapeutics for Melanoma by companies and universities/research institutes based on information derived from company and industry-specific sources
The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved Melanoma therapeutics and enlists all their major and minor projects
The report assesses Melanoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news related to pipeline therapeutics for Melanoma
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategiesIdentify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Identify and understand important and diverse types of therapeutics under development for Melanoma
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Melanoma pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies mentioned
4SC AG
AB Science SA
AbbVie Inc
Abivax SA
Acetylon Pharmaceuticals Inc
Adamis Pharmaceuticals Corp
Adaptimmune Therapeutics Plc
Adicet Bio Inc
Aduro BioTech Inc
Advanced Cancer Therapeutics
Advaxis Inc
Aeterna Zentaris Inc
Affichem SA
Agalimmune Ltd
Agenus Inc
Agilvax Inc
AGV Discovery SAS
AIMM Therapeutics BV
Alethia Biotherapeutics Inc
Altor BioScience Corp
Amgen Inc
Anavex Life Sciences Corp
Angimmune LLC
Antibe Therapeutics Inc
Antigen Express Inc
APEIRON Biologics AG
Apexigen Inc
Aphios Corp
APO-T BV
Apogenix GmbH
Aposense Ltd
Aptose Biosciences Inc
Arisaph Pharmaceuticals Inc
ARMO Biosciences Inc
Array BioPharma Inc
Asana BioSciences LLC
Astellas Pharma Inc
Astex Pharmaceuticals Inc
AstraZeneca Plc
Aurigene Discovery Technologies Ltd
Azaya Therapeutics Inc
Basilea Pharmaceutica Ltd
Batu Biologics Inc
Bayer AG
BeiGene Ltd
Beijing Kawin Technology Share-Holding Co Ltd
Bellicum Pharmaceuticals Inc
BerGenBio AS
Bio-Cancer Treatment International Ltd
Biocad
Biogazelle NV
Biogenomics Ltd
BioLineRx Ltd
Bioncotech Therapeutics SL
Bionomics Ltd
BioNTech AG
Biothera Pharmaceutical Inc
Biovista Inc
Boehringer Ingelheim GmbH
Boston Biomedical Inc
Bristol-Myers Squibb Company
Calithera Biosciences Inc
Can-Fite BioPharma Ltd
CCRP Therapeutics GmbH
Cellceutix Corp
Celldex Therapeutics Inc
Celprogen Inc
Celyad SA
Checkmate Pharmaceuticals Inc
Chipscreen Biosciences Ltd
Chugai Pharmaceutical Co Ltd
Cipher Pharmaceuticals Inc
Cornerstone Pharmaceuticals Inc
Cortice Biosciences Inc
Corvus Pharmaceuticals Inc
CytomX Therapeutics Inc
Cytune Pharma SAS
CyTuVax BV
CZ BioMed Corp
Daiichi Sankyo Company Ltd
Deciphera Pharmaceuticals LLC
DEKK-TEC Inc
Dicerna Pharmaceuticals Inc
DormaTarg Inc
Dynavax Technologies Corp
Eisai Co Ltd
Eli Lilly and Company
Elsalys Biotech SAS
Ensol Biosciences Inc
EntreChem SL
eTheRNA Immunotherapies NV
Evelo Therapeutics Inc
Exelixis Inc
F. Hoffmann-La Roche Ltd
Faes Farma SA
Five Prime Therapeutics Inc
Formune SL
Galapagos NV
Galectin Therapeutics Inc
Genelux Corp
Genocea Biosciences Inc
Genzyme Corp
GlaxoSmithKline Plc
Gradalis Inc
GreenPeptide Co Ltd
Hadasit Medical Research Services & Development Ltd
HanAll Biopharma Co Ltd
Hanmi Pharmaceuticals Co Ltd
Heat Biologics Inc
HEC Pharm Co Ltd
Hemispherx Biopharma Inc
Histogen Inc
Horizon Pharma Plc
Humorigin Biotechnology Corp
Idera Pharmaceuticals Inc
Ignyta Inc
Immodulon Therapeutics Ltd
Immune Design Corp
Immune Response BioPharma Inc
ImmunGene Inc
Immunocore Ltd
ImmunoGen Inc
Immupharma Plc
ImmuRx Inc
IMPACT Therapeutics Inc
Imugene Ltd
Incuron LLC
Incyte Corp
Infinity Pharmaceuticals Inc
Inovio Pharmaceuticals Inc
InteRNA Technologies BV
IO Biotech ApS
JHL Biotech Inc
Jiangsu Hengrui Medicine Co Ltd
Johnson & Johnson
KaloBios Pharmaceuticals Inc
Kancera AB
Karyopharm Therapeutics Inc
Kite Pharma Inc
Kura Oncology Inc
Lentigen Technology Inc
Life Science Pharmaceuticals Inc
Lindis Biotech GmbH
Lion Biotechnologies Inc
Lipotek Pty Ltd
Loxo Oncology, Inc.
Lupin Ltd
Lytix Biopharma AS
MacroGenics Inc
Magnus Life Ltd
MaxiVAX SA
MediaPharma srl
Medicenna Therapeutics Inc
MedImmune LLC
Medisyn Technologies Inc
Medivation Inc
MELEMA Pharma GmbH
Merck & Co Inc
Merck KGaA
Millennium Pharmaceuticals Inc
Modulate Therapeutics Inc
Molecular Templates Inc
Moleculin Biotech Inc
Morphotek Inc
Nektar Therapeutics
Neonc Technologies Inc
Nerviano Medical Sciences Srl
Neumedicines Inc
NewLink Genetics Corp
NormOxys Inc
Northwest Biotherapeutics Inc
Novartis AG
Novogen Ltd
Omeros Corp
Oncology Research International Ltd
Oncolys BioPharma Inc
Oncolytics Biotech Inc
OncoNOx ApS
OncoSec Medical Inc
OncoTartis Inc
Oncovir Inc
Onxeo SA
Orega Biotech SAS
OSE Immunotherapeutics
Pacific Northwest Biotechnology LLC
Patrys Ltd
PepTx Inc
PepVax Inc
Pfizer Inc
Pharmicell Co Ltd
Pharminox Ltd
Pharmis Biofarmaceutica Lda
Philogen SpA
PinCell srl
Pivotal BioSciences Inc
Plexxikon Inc
Polaris Pharmaceuticals Inc
Polyplus-Transfection SA
Prima BioMed Ltd
Propanc Health Group Corp
Provectus Biopharmaceuticals Inc
Provenance Biopharmaceuticals Corp
Qu Biologics Inc
Reata Pharmaceuticals Inc
Recepta Biopharma SA
Recombio SL
Rexahn Pharmaceuticals Inc
Rgenix Inc
Rigontec GmbH
RXi Pharmaceuticals Corp
Sapvax
SATT North SAS
Scancell Holdings Plc
SilaGene Inc
Sillajen Biotherapeutics
SolaranRx Inc
Sorrento Therapeutics Inc
Spotlight Innovation Inc
Sumitomo Dainippon Pharma Co Ltd
Sun Pharma Advanced Research Company Ltd
Susavion Biosciences Inc
SuviCa Inc
Syndax Pharmaceuticals Inc
Taiga Biotechnologies Inc
TaiRx Inc
Taiwan Liposome Company Ltd
Takara Bio Inc
Takeda Pharmaceutical Company Ltd
Takis Srl
Tara Immuno-Oncology Therapeutics LLC
Targovax ASA
TC BioPharm Ltd
TetraLogic Pharmaceuticals
Theravectys SA
Tikcro Technologies Ltd
TILT Biotherapeutics Ltd
Tiltan Pharma Ltd
Tocagen Inc
TREAT U SA
TVAX Biomedical Inc
TyrNovo Ltd
UbiVac LLC
Ultimovacs AS
UNC Health Care
Vaccibody AS
Vascular Biogenics Ltd
Vault Pharma Inc
Vaxenta Biotechnologies
Vichem Chemie Research Ltd
Viralytics Ltd
ViraTherapeutics GmbH
Virttu Biologics Ltd
VLP Therapeutics LLC
WntResearch AB
X4 Pharmaceuticals Inc
ZIOPHARM Oncology Inc
Table of Contents
List of Tables
List of Figures
Pricing
Discounts available for multiple purchases.